论文部分内容阅读
目的初步观察益赛普(重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白)治疗幼年特发性关节炎的疗效。方法 38例于2007年6月至2011年2月间诊治的幼年特发性关节炎患者,年龄3～13岁,在常规抗风湿药物治疗基础上加用益赛普0.4mg/kg皮下注射,每周2次,连续治疗3个月。观察治疗后2、4、8和12周时相关临床症状和生化指标的变化,并应用健康评价问卷进行测试。结果治疗2周有效率28.1%;4周有效率34.2%;8周有效率50.8%;12周有效率60.5%。12周体温控制的有效率为86.8%,关节症状改善的有效率可达84.2%。不良反应为注射部位反应、皮疹、呼吸道感染、消化道症状、失眠、便秘等。用药期间未发生严重不良反应。结论益赛普能有效缓解幼年特发性关节炎的症状,并改善病情活动指标,降低致残率,提高患者生活质量。
Objective To observe the curative effect of Yisip (recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein) in the treatment of juvenile idiopathic arthritis. Methods Thirty-eight patients with juvenile idiopathic arthritis who were diagnosed and treated between June 2007 and February 2011 were aged 3 to 13 years old. On the basis of conventional anti-rheumatic drugs, subcutaneous injection with 0.4 mg / kg of etanercept 2 times a week, continuous treatment for 3 months. The changes of clinical symptoms and biochemical indexes at 2, 4, 8 and 12 weeks after treatment were observed and tested by health assessment questionnaire. Results The effective rate was 28.1% in 2 weeks, 34.2% in 4 weeks, 50.8% in 8 weeks and 60.5% in 12 weeks. The effective rate of body temperature control in 12 weeks was 86.8%, and the effective rate of improvement of joint symptoms was 84.2%. Adverse reactions to the injection site reactions, rash, respiratory infections, gastrointestinal symptoms, insomnia, constipation and so on. Serious adverse reactions did not occur during the treatment. Conclusion Yisipu can effectively alleviate the symptoms of juvenile idiopathic arthritis, and improve the index of disease activity, reduce the morbidity and improve the quality of life of patients.